Sep 30, 2019

Enliven Therapeutics Q3 2019 Earnings Report

EPS
-$1.53
Research and Development Expenses
$5.14M
General and Administrative Expenses
$1.74M
Gross Profit
$0

Enliven Therapeutics

Enliven Therapeutics